Analysis of Mural Cell Recruitment to Tumor Vessels
暂无分享,去创建一个
[1] Holger Gerhardt,et al. Lack of Pericytes Leads to Endothelial Hyperplasia and Abnormal Vascular Morphogenesis , 2001, The Journal of cell biology.
[2] Philippe Soriano,et al. The two PDGF receptors maintain conserved signaling in vivo despite divergent embryological functions. , 2001, Molecular cell.
[3] N. Copeland,et al. A novel transgenic marker for migrating limb muscle precursors and for vascular smooth muscle cells , 2001, Developmental dynamics : an official publication of the American Association of Anatomists.
[4] C. Heldin,et al. Retention of PDGFR-beta function in mice in the absence of phosphatidylinositol 3'-kinase and phospholipase Cgamma signaling pathways. , 2000, Genes & development.
[5] A. Porteu,et al. An overlapping CArG/octamer element is required for regulation of desmin gene transcription in arterial smooth muscle cells. , 2000, Developmental biology.
[6] Peter Carmeliet,et al. VEGF gene therapy: stimulating angiogenesis or angioma-genesis? , 2000, Nature Medicine.
[7] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[8] H. Blau,et al. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. , 2000, Circulation.
[9] R K Jain,et al. Openings between defective endothelial cells explain tumor vessel leakiness. , 2000, The American journal of pathology.
[10] P. Donahoe,et al. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[11] H. Augustin,et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. , 2000, Cancer research.
[12] Dian Feng,et al. Heterogeneity of the Angiogenic Response Induced in Different Normal Adult Tissues by Vascular Permeability Factor/Vascular Endothelial Growth Factor , 2000, Laboratory Investigation.
[13] Napoleone Ferrara,et al. Clinical applications of angiogenic growth factors and their inhibitors , 1999, Nature Medicine.
[14] G. Yancopoulos,et al. In Situ Expression of Angiopoietins in Astrocytomas Identifies Angiopoietin-2 as an Early Marker of Tumor Angiogenesis , 1999, Experimental Neurology.
[15] M. Bissell. Tumor plasticity allows vasculogenic mimicry, a novel form of angiogenic switch. A rose by any other name? , 1999, The American journal of pathology.
[16] P. Meltzer,et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. , 1999, The American journal of pathology.
[17] C. Betsholtz,et al. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. , 1999, Development.
[18] B. Brooke,et al. Defective angiogenesis in mice lacking endoglin. , 1999, Science.
[19] D. Pode,et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. , 1999, The Journal of clinical investigation.
[20] K. Hirschi,et al. PDGF, TGF-β, and Heterotypic Cell–Cell Interactions Mediate Endothelial Cell–induced Recruitment of 10T1/2 Cells and Their Differentiation to a Smooth Muscle Fate , 1998, The Journal of cell biology.
[21] E. Keshet,et al. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. , 1998, Development.
[22] B R Johansson,et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. , 1997, Science.
[23] Pamela F. Jones,et al. Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis , 1996, Cell.
[24] Thomas N. Sato,et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation , 1995, Nature.
[25] M. Gertsenstein,et al. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. , 1994, Genes & development.
[26] Philippe Soriano,et al. Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice. , 1994, Genes & development.
[27] B Swolin,et al. Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. , 1994, Genes & development.
[28] D. Ruiter,et al. Differential expression of markers for endothelial cells, pericytes, and basal lamina in the microvasculature of tumors and granulation tissue. , 1991, The American journal of pathology.
[29] R K Jain,et al. Determinants of tumor blood flow: a review. , 1988, Cancer research.
[30] M. Jaye,et al. Modulation of the sis gene transcript during endothelial cell differentiation in vitro. , 1985, Science.
[31] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.